Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Caution when lean body weight is used as a size descriptor for obese subjects.

Literature DB >> 12496756

Caution when lean body weight is used as a size descriptor for obese subjects.

Bruce Green, Stephen Duffull.

Abstract

Entities: Disease

Mesh：

Year: 2002 PMID： 12496756 DOI： 10.1067/mcp.2002.129306

Source DB: PubMed Journal: Clin Pharmacol Ther ISSN： 0009-9236 Impact factor: 6.875

Keyword Cloud
Cited

× No keyword cloud information.

17 in total

Review 1. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007.

Authors: Sarah C McLeay; Glynn A Morrish; Carl M J Kirkpatrick; Bruce Green
Journal: Clin Pharmacokinet Date: 2012-05-01 Impact factor: 6.447

2. Predictive performance of the 'Minto' remifentanil pharmacokinetic parameter set in morbidly obese patients ensuing from a new method for calculating lean body mass.

Authors: Luca La Colla; Andrea Albertin; Giorgio La Colla; Andrea Porta; Giorgio Aldegheri; Domenico Di Candia; Fausto Gigli
Journal: Clin Pharmacokinet Date: 2010 Impact factor: 6.447

3. Pharmacokinetic model-driven remifentanil administration in the morbidly obese: the 'critical weight' and the 'fictitious height', a possible solution to an unsolved problem?

Authors: L La Colla; A Albertin; G La Colla
Journal: Clin Pharmacokinet Date: 2009 Impact factor: 6.447

4. Translational Modeling and Simulation in Supporting Early-Phase Clinical Development of New Drug: A Learn-Research-Confirm Process.

Authors: Dongyang Liu; Yi Zhang; Ji Jiang; John Choi; Xuening Li; Dalong Zhu; Dawei Xiao; Yanhua Ding; Hongwei Fan; Li Chen; Pei Hu
Journal: Clin Pharmacokinet Date: 2017-08 Impact factor: 6.447

5. Physiological modeling for indirect evaluation of drug tissular pharmacokinetics under non-steady-state conditions: an example of antimicrobial prophylaxis during liver surgery.

Authors: Franck Lagneau; Jean Marty; Pascale Beyne; Michel Tod
Journal: J Pharmacokinet Pharmacodyn Date: 2005-02 Impact factor: 2.745

Caution when lean body weight is used as a size descriptor for obese subjects.

Review 1. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007.

2. Predictive performance of the 'Minto' remifentanil pharmacokinetic parameter set in morbidly obese patients ensuing from a new method for calculating lean body mass.

3. Pharmacokinetic model-driven remifentanil administration in the morbidly obese: the 'critical weight' and the 'fictitious height', a possible solution to an unsolved problem?

4. Translational Modeling and Simulation in Supporting Early-Phase Clinical Development of New Drug: A Learn-Research-Confirm Process.

5. Physiological modeling for indirect evaluation of drug tissular pharmacokinetics under non-steady-state conditions: an example of antimicrobial prophylaxis during liver surgery.

6. Quantification of lean bodyweight.

7. Moxifloxacin dosing in post-bariatric surgery patients.

8. Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes.

Review 9. What is the best size descriptor to use for pharmacokinetic studies in the obese?

10. Development of a dosing strategy for enoxaparin in obese patients.